{"title":"High Heart: A Role for Calcineurin Signaling in Hypoxia-Influenced Cardiac Growth.","authors":"TyAnna L Lovato, Richard M Cripps","doi":"10.1161/CIRCGENETICS.117.001919","DOIUrl":null,"url":null,"abstract":"In 1925, Dr Carlos Monge presented to the National Academy of Medicine in Lima, Peru, his observations of a new disease. His patient had bluish skin, dizziness, and confusion when working at high altitudes, but symptoms were ameliorated once the patient returned to the coast.1 In a storied and impactful career, Monge went on to study the physiological differences between sufferers of Monge’s disease, those who were able to acclimatize to the altitude, and finally those who thrived in the low oxygen conditions.2 Today, we now know this condition as chronic mountain sickness (CMS). Caused by exposure to low oxygen conditions, CMS affects a significant proportion of high-altitude populations and can lead to pulmonary hypertension, cardiac hypertrophy, and eventual heart failure.3\n\nSee Article by Zarndt and Walls et al \n\nToday, CMS still afflicts a large number of individuals, including a striking one sixth of residents of Cerro de Pasco in Peru,4 designating CMS as a significant medical challenge in many high-altitude populations. Understanding the mechanisms by which hypertension and cardiac hypertrophy occur as a result of hypoxia is important not only …","PeriodicalId":10277,"journal":{"name":"Circulation: Cardiovascular Genetics","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1161/CIRCGENETICS.117.001919","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation: Cardiovascular Genetics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1161/CIRCGENETICS.117.001919","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In 1925, Dr Carlos Monge presented to the National Academy of Medicine in Lima, Peru, his observations of a new disease. His patient had bluish skin, dizziness, and confusion when working at high altitudes, but symptoms were ameliorated once the patient returned to the coast.1 In a storied and impactful career, Monge went on to study the physiological differences between sufferers of Monge’s disease, those who were able to acclimatize to the altitude, and finally those who thrived in the low oxygen conditions.2 Today, we now know this condition as chronic mountain sickness (CMS). Caused by exposure to low oxygen conditions, CMS affects a significant proportion of high-altitude populations and can lead to pulmonary hypertension, cardiac hypertrophy, and eventual heart failure.3
See Article by Zarndt and Walls et al
Today, CMS still afflicts a large number of individuals, including a striking one sixth of residents of Cerro de Pasco in Peru,4 designating CMS as a significant medical challenge in many high-altitude populations. Understanding the mechanisms by which hypertension and cardiac hypertrophy occur as a result of hypoxia is important not only …
期刊介绍:
Circulation: Genomic and Precision Medicine considers all types of original research articles, including studies conducted in human subjects, laboratory animals, in vitro, and in silico. Articles may include investigations of: clinical genetics as applied to the diagnosis and management of monogenic or oligogenic cardiovascular disorders; the molecular basis of complex cardiovascular disorders, including genome-wide association studies, exome and genome sequencing-based association studies, coding variant association studies, genetic linkage studies, epigenomics, transcriptomics, proteomics, metabolomics, and metagenomics; integration of electronic health record data or patient-generated data with any of the aforementioned approaches, including phenome-wide association studies, or with environmental or lifestyle factors; pharmacogenomics; regulation of gene expression; gene therapy and therapeutic genomic editing; systems biology approaches to the diagnosis and management of cardiovascular disorders; novel methods to perform any of the aforementioned studies; and novel applications of precision medicine. Above all, we seek studies with relevance to human cardiovascular biology and disease.